MedTrace Logo

MOre REsponse on Cardiac Resynchronization Therapy With MultiPoint Pacing

NCT02006069 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 5850

Last updated 2023-05-17

Study results available
· View outcomes & findings →

Summary

The purpose of this Clinical investigation is to assess the impact of the Multi Point Pacing (MPP) feature at 12 months in the treatment of patients not responding to standard Cardiac Resynchronization Therapy (CRT) after 6 months.

Conditions

Interventions

DEVICE

MPP

All patients enrolled in the study will be implanted (according to current Guidelines) with an MPP compatible CRT device. The MPP feature will be evaluated in two study phases. Patients randomized to MPP in Phase I will have MPP programmed per the physician's discretion ("no mandated MPP programming") and patients randomized to MPP in Phase II will have MPP programmed per protocol requirements ("mandated MPP programming").

Sponsors & Collaborators

  • Abbott Medical Devices

    lead INDUSTRY

Principal Investigators

  • Christophe Leclercq · Centre Cardio-Pneumologique, CHU Pontchaillou

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-12-31
Primary Completion
2021-05-30
Completion
2021-05-30

Countries

  • United States
  • Australia
  • Austria
  • Belgium
  • Canada
  • China
  • Colombia
  • Denmark
  • Finland
  • France
  • Germany
  • Greece
  • India
  • Israel
  • Italy
  • Lebanon
  • Malaysia
  • Malta
  • Netherlands
  • Poland
  • Portugal
  • Puerto Rico
  • Saudi Arabia
  • Singapore
  • South Korea
  • Spain
  • Sweden
  • Switzerland
  • Taiwan
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02006069 on ClinicalTrials.gov